Imricor Medical Systems (ASX:IMR) Piotroski F-Score: 3 (As of Jul. 13, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IMR Imricor Medical Systems Inc ASX:IMR
43 GF Score
Price A$1.83
GF Value A$0.10
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Imricor Medical Systems Piotroski F-Score?

Imricor Medical Systems ASX:IMR 43 Piotroski F-Score is 3 as of Jul. 13, 2026, which is at its 10-year median of 3.00. GuruFocus rates ASX:IMR with a GF Score™ of 43/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Imricor Medical Systems ranks worse than 77.21% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Imricor Medical Systems has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Imricor Medical Systems's Piotroski F-Score or its related term are showing as below:

ASX:IMR' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 4
Current: 3

During the past 8 years, the highest Piotroski F-Score of Imricor Medical Systems was 4. The lowest was 3. And the median was 3.

Imricor Medical Systems  (ASX:IMR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Imricor Medical Systems Piotroski F-Score Related Terms


Imricor Medical Systems Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Imricor Medical Systems's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imricor Medical Systems Piotroski F-Score Chart

Imricor Medical Systems Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 3.00 3.00 3.00 4.00 3.00

Imricor Medical Systems Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 0.00 4.00 0.00 3.00

ASX:IMR vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Imricor Medical Systems's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imricor Medical Systems Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Imricor Medical Systems's Piotroski F-Score falls into.


ASX:IMR
43GF Score
Imricor Medical Systems Inc ASX:IMR
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was A$-38.11 Mil.
Cash Flow from Operations was A$-28.72 Mil.
Revenue was A$0.44 Mil.
Gross Profit was A$-3.06 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (34.144 + 68.864) / 2 = A$51.504 Mil.
Total Assets at the begining of this year (Dec24) was A$34.14 Mil.
Long-Term Debt & Capital Lease Obligation was A$20.92 Mil.
Total Current Assets was A$64.59 Mil.
Total Current Liabilities was A$26.14 Mil.
Net Income was A$-46.89 Mil.

Revenue was A$1.51 Mil.
Gross Profit was A$-1.46 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (12.412 + 34.144) / 2 = A$23.278 Mil.
Total Assets at the begining of last year (Dec23) was A$12.41 Mil.
Long-Term Debt & Capital Lease Obligation was A$32.97 Mil.
Total Current Assets was A$28.97 Mil.
Total Current Liabilities was A$3.72 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Imricor Medical Systems's current Net Income (TTM) was -38.11. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Imricor Medical Systems's current Cash Flow from Operations (TTM) was -28.72. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-38.105/34.144
=-1.11600867

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-46.885/12.412
=-3.77739285

Imricor Medical Systems's return on assets of this year was -1.11600867. Imricor Medical Systems's return on assets of last year was -3.77739285. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Imricor Medical Systems's current Net Income (TTM) was -38.11. Imricor Medical Systems's current Cash Flow from Operations (TTM) was -28.72. ==> -28.72 > -38.11 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=20.924/51.504
=0.40625971

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=32.968/23.278
=1.41627288

Imricor Medical Systems's gearing of this year was 0.40625971. Imricor Medical Systems's gearing of last year was 1.41627288. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=64.59/26.143
=2.47064224

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=28.973/3.72
=7.78844086

Imricor Medical Systems's current ratio of this year was 2.47064224. Imricor Medical Systems's current ratio of last year was 7.78844086. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Imricor Medical Systems's number of shares in issue this year was 308.749. Imricor Medical Systems's number of shares in issue last year was 223.999. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-3.061/0.439
=-6.97266515

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-1.459/1.514
=-0.96367239

Imricor Medical Systems's gross margin of this year was -6.97266515. Imricor Medical Systems's gross margin of last year was -0.96367239. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=0.439/34.144
=0.01285731

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=1.514/12.412
=0.12197873

Imricor Medical Systems's asset turnover of this year was 0.01285731. Imricor Medical Systems's asset turnover of last year was 0.12197873. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Imricor Medical Systems has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Imricor Medical Systems (ASX:IMR) has a Piotroski F-Score of 3 as of Jul. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Imricor Medical Systems and its competitors. This is near median its historical median of 3.00. Over the past decade, Imricor Medical Systems' Piotroski F-Score has ranged from 3.00 to 4.00. According to the industry distribution chart, Imricor Medical Systems ranks #620 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 77.2%.
Is Imricor Medical Systems' Piotroski F-Score too high?
Imricor Medical Systems' current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 4.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Imricor Medical Systems' value of 3 is 40% below this industry median. Based on the distribution chart, Imricor Medical Systems ranks #620 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #620 out of 803 companies for Piotroski F-Score. This places Imricor Medical Systems in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Imricor Medical Systems' value of 3 is 40% below this benchmark. Historically, Imricor Medical Systems' own Piotroski F-Score has ranged from 3.00 to 4.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Imricor Medical Systems has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imricor Medical Systems's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Imricor Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.83 — trading 1725% above its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 40% below the Medical Devices & Instruments industry median of 5.00. Imricor Medical Systems' overall GF Score™ is 43/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Piotroski F-Score is 3 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued. The current stock price of A$1.83 is trading 1725% above its estimated GF Value™ of A$0.10. GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.

Key valuation signals for ASX:IMR:

  • Piotroski F-Score: 3 (near median its 10-year median of 3.00)
  • GF Value™: A$0.10 vs. price of A$1.83 (1725% above fair value)
  • GF Score™: 43/100 with 10 warning signs
  • Industry Position: 40% below the Medical Devices & Instruments median (#620 of 803)

No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Imricor Medical Systems Business Description

Address 400 Gateway Boulevard, Burnsville, MN, USA, 55337
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
43GF Score

Get the complete analysis for ASX:IMR

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.83
Price
A$0.10
GF Value